{
    "clinical_study": {
        "@rank": "109476", 
        "brief_summary": {
            "textblock": "Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting\n      women of childbearing age.  Currently, there is no effective therapy for the disease and the\n      prognosis is poor.\n\n      This study is designed to determine the disease processes involved at the level of cells and\n      molecules, in order to develop more effective therapy.\n\n      Researchers intend to identify the proteins and genes that contribute to the process of lung\n      destruction in affected individuals."
        }, 
        "brief_title": "Study of the Disease Process of Lymphangioleiomyomatosis", 
        "condition": [
            "Lung Disease", 
            "Pneumothorax", 
            "Tuberous Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Pneumothorax", 
                "Sclerosis", 
                "Tuberous Sclerosis", 
                "Lymphangioleiomyomatosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease.\n       Most of them are females of childbearing age.  Currently, there is no proven effective\n      therapy and the prognosis is variable.  This study is designed to (a) define the clinical\n      course of the disease and (b) elucidate the pathogenesis of the disease at the cellular and\n      molecular levels, in order to develop more effective therapy.  To accomplish this, we intend\n      to identify the proteins and genes that contribute to the process of lung destruction in\n      affected individuals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA:\n\n        General admission criteria for patients include one or both of the following:\n\n        Findings on lung biopsy diagnostic of LAM;\n\n        Findings on chest x-ray and/or chest computed axial tomography consistent with LAM.\n\n        Patients with TSC and pulmonary LAM will be included in the study.\n\n        Normal non-smokers in the control group are defined as individuals who have not smoked for\n        greater than or equal to 1 year and have no systemic or pulmonary disease.\n\n        Normal smokers defined as individuals with no systemic or pulmonary disease, who have\n        smoked for greater than or equal to 1 year and have normal chest x-ray and normal\n        pulmonary function tests may be included if needed as controls for a similar population of\n        patients with LAM.\n\n        EXCLUSION CRITERIA:\n\n        Exclusion criteria for patients include:\n\n        Age less than 16.\n\n        Advanced stage of a pulmonary or a systemic illness in which the risk of the study is\n        judged to be significant even in the absence of a clear contraindication to the\n        procedures.\n\n        Exclusion criteria for patients for the formal exercise study and the stress\n        echocardiogram include patients on continuous oxygen.  Patients may perform an exercise\n        test that will assess the patient's exercise capacity with activities of daily living."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "99999999", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001465", 
            "org_study_id": "950186", 
            "secondary_id": "95-H-0186"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smooth Muscle Proliferation", 
            "Bronchoscopy", 
            "Female", 
            "Pneumothorax", 
            "Tuberous Sclerosis", 
            "Lymphangioleiomyomatosis (LAM)"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1995-H-0186.html"
        }, 
        "location": {
            "contact": {
                "email": "prpl@mail.cc.nih.gov", 
                "last_name": "For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)", 
                "phone": "800-411-1222", 
                "phone_ext": "TTY8664111010"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)", 
        "overall_contact": {
            "email": "mhaughey@nhlbi.nih.gov", 
            "last_name": "Mary Haughey, R.N.", 
            "phone": "(301) 496-3632"
        }, 
        "overall_contact_backup": {
            "email": "mossj@nhlbi.nih.gov", 
            "last_name": "Joel Moss, M.D.", 
            "phone": "(301) 496-1597"
        }, 
        "overall_official": {
            "affiliation": "National Heart, Lung, and Blood Institute (NHLBI)", 
            "last_name": "Joel Moss, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "15583138", 
                "citation": "Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17462-7. Epub 2004 Dec 6."
            }, 
            {
                "PMID": "11893686", 
                "citation": "Pacheco-Rodriguez G, Kristof AS, Stevens LA, Zhang Y, Crooks D, Moss J. Giles F. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis. Chest. 2002 Mar;121(3 Suppl):56S-60S."
            }, 
            {
                "PMID": "12958050", 
                "citation": "Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA, Rabel A, Travis WD, Moss J. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2003 Dec 15;168(12):1427-31. Epub 2003 Sep 4."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001465"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1995", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }, 
    "geocoordinates": {
        "National Institutes of Health Clinical Center, 9000 Rockville Pike": "38.985 -77.095"
    }
}